Compare PRTA & NECB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRTA | NECB |
|---|---|---|
| Founded | 2012 | 1934 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Savings Institutions |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 429.2M | 392.6M |
| IPO Year | 2013 | 2021 |
| Metric | PRTA | NECB |
|---|---|---|
| Price | $8.15 | $28.22 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 2 |
| Target Price | $21.40 | ★ $31.50 |
| AVG Volume (30 Days) | ★ 420.1K | 50.0K |
| Earning Date | 11-05-2026 | 10-22-2026 |
| Dividend Yield | N/A | ★ 3.55% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 2.25 |
| Revenue | ★ $814,000.00 | N/A |
| Revenue This Year | $775.41 | $2.26 |
| Revenue Next Year | N/A | $18.16 |
| P/E Ratio | ★ N/A | $12.54 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.70 | $19.96 |
| 52 Week High | $11.80 | $30.50 |
| Indicator | PRTA | NECB |
|---|---|---|
| Relative Strength Index (RSI) | 45.82 | 42.58 |
| Support Level | $8.01 | $25.83 |
| Resistance Level | $9.14 | $28.94 |
| Average True Range (ATR) | 0.44 | 0.70 |
| MACD | -0.01 | -0.19 |
| Stochastic Oscillator | 37.55 | 5.08 |
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.
NorthEast Community Bancorp Inc operates as a community-oriented financial institution. It is principally engaged in the business of attracting deposits and investing those funds into mortgage and commercial loans. It conducts activities throughout the Northeastern United States, including New York, Massachusetts, New Jersey, and Connecticut. The company offers a comprehensive line of banking products and services, including mobile banking as well as commercial real estate loans, commercial construction financing, lines of credit, and term loans. It also offers investment advisory and financial planning services.